Event Date

Jul 31


CAB PrEP resource sheet
CAB PrEP – PrEP Learning Network webinar presentation, recording, key takeaways
MOSAIC project brief

In 2020, two clinical trials (HPTN 083 and HPTN 084) demonstrated that injectable cabotegravir for PrEP is safe and is highly efficacious at preventing HIV infection across a range of populations, and in December 2021 the FDA approved injectable cabotegravir as PrEP (CAB PrEP; brand name ‘Apretude’). As the first injectable form of HIV PrEP, CAB PrEP is a much-needed addition to an expanding array of prevention options. To ensure this option transforms into real choice for those who could benefit from it, barriers to rollout of CAB PREP, solutions to overcome them and strategies to address and avoid pitfalls associated with early introduction of oral PrEP must be well understood by implementers, policymakers, funders, advocates and communities. This workshop will explore what is needed to ensure that introductory research and programs are strategically designed, user-centered, and appropriately resourced to support successful rollout of CAB PrEP.

Sunday, 31 July, 10:30 am – 12:00 pm ET
Palais des congrès de Montréal Room 524 / Channel 9

Saiqa Mullick, Wits Reproductive Health Institute (RHI), South Africa      
Patriciah Jeckonia, LVCT Health, Kenya
Rachel Baggaley, WHO
Imelda Mahaka, Pangaea Zimbabwe AIDS Trust (PZAT)
Hasina Subedar, South Africa NDOH
Elizabeth Irungu, Jhpiego
Jason Zucker, Columbia University
Midnight Poonkasetwattana, APCOM, Thailand
Shakirah Namwanje, UNASO, Uganda